Inclusion Criteria:  For all patients  Compensated liver disease defined by the following criteria: Conjugated bilirubin level ≤ 1.2 x upper limit of normal (ULN), TP / INR ≤ 1.2 × ULN, platelets ≥ 150 x 109 / L, serum albumin ≥ 35 g / L, and no history of clinical hepatic decompensation (ascites, jaundice, encephalopathy, variceal hemorrhage) (results from a blood test dating up to 8 months before inclusion). Adequate haematological function: platelets ≥ 150x109 / L, Hb ≥ 12 g / dL (male) or ≥ 11 g / dL (female), white blood cells ≥4x109 / L and <11x109 / L, except for ethnic neutropenia (these values must be obtained at least 8 months before inclusion) Male or female between 20 and 69 years of age, inclusive 18.5 ≤BMI ≤ 35 kg / m² Patients who dated and signed informed consent  For patients chronically infected with NUC treatment for more than 6 months:  HBV DNA <25 IU / mL HBsAg-positive (≥100 IU / mL) HBeAg-negative or positive ALT <1.5x ULN  For chronically infected, untreated patients:  HBsAg positive (≥100 IU / mL) negative or positive HBeAg HBV DNA> 2000 IU / mL ALT <2 x ULN  Exclusion Criteria:  Use of steroids or other immunosuppressive agents that would affect the number and / or function of immune cells in the last 4 weeks  •,Any disease or other major medical disorder or condition that , that, in the judgment of the investigator, would interfere with results of the study (including, but not limited to: cancer, systemic lupus erythematosus, rheumatoid arthritis or other autoimmune disease, etc. ...)  Major surgery or traumatic injury (including blood transfusion) in the last 4 weeks  -• Use of an experimental drug in the last 12 weeks  Positive test for Hepatitis C, HIV, Hepatitis D, or Hepatitis A (anti-HAV IgM) at the time of inclusion Significant acute infection such as influenza or other clinically significant illness in the last 2 weeks History of drug abuse in the last year positive pregnancy test for women of childbearing age Breast-feeding women  Patients presenting:  a medical history or signs of cirrhosis defined by a biopsy result or any other non-invasive validated test showing cirrhosis, OR Either during the selection visit: a transient elastography value ≥ 10.5 kPa OR a Fibrotest® / Fibrosure® score ≥ 0.48 and an APRI score ≥1 .  Note: If a biopsy or a non-invasive test for cirrhosis has never been performed in the patient, then the medical examinations described in b) must be performed during the selection visit.  History of ascites, digestive hemorrhage and / or encephalopathy Any co-morbidity that could lead to liver damage as judged by the investigator (excessive alcohol consumption, hemochromatosis, Wilson's disease, autoimmune hepatitis, inflammatory colitis ...) Patients unable or unwilling to comply with the protocol requirements Patient unable to give informed consent